Why the study?
Does candesartan improve hypertension and proteinuria in a patient with nephrotic syndrome associated with renovascular hypertension?
Does candesartan improve hypertension and proteinuria in a patient with nephrotic syndrome associated with renovascular hypertension?
Candesartan may be a promising agent for treating renovascular hypertension complicated by massive proteinuria and renal insufficiency.
Candesartan may control hypertension and proteinuria without renal worsening in this case; hypothesis-generating and leaves open need for controlled trials.
A sixty eight-year-old man was referred to our hospital for evaluation of hypertension and hypokalemia. His chief complaints were fatigability and weakness of the lower extremities. Atrophy of the right kidney was noted on computed tomography. The laboratory findings demonstrated massive proteinuria, markedly elevated plasma renin activity, hypokalemia, and renal insufficiency. Angiography showed total occlusion of the right renal artery. The patient was diagnosed as having nephrotic syndrome associated with renovascular hypertension. Treatment with candesartan, an angiotensin-II-receptor blocker (ARB), controlled both hypertension and proteinuria satisfactorily without worsening of his renal function. This is the first report on the effect of ARB on nephrotic syndrome associated with renovascular hypertension. Based on the results, ARB can be considered a promising agent for the treatment of patients with renovascular hypertension with massive proteinuria and renal insufficiency.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: